We have launched a phase-II trial to assess SSTR2 expression by 68Ga-DOTATATE PET/CT in symptomatic relapsing and refractory multiple myeloma patients (SCARLET trial—NCT04379817). This evidence concerns the gene SSTR2 and plasma cell myeloma.